Gastrointestinal chronic graft-versus-host disease: Management options

Farrukh Awan, Mehdi Hamadani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is a common and debilitating condition afflicting a number of allogeneic stem cell recipients more than 100 days after their transplant. Limited options are available for the acute management of patients with severe gastrointestinal (GI) symptoms including gastric bleeding. Along with increased immunosuppression and aggressive supportive care, we report here the use of aminocaproic acid in the management of patients with GI bleeding resulting from severe GVHD. The use of aminocaproic acid enabled us to reduce the frequency and number of blood product transfusions required to manage our patient. Anti-fibrinolytic agents may therefore serve as useful adjunctive but underutilized therapy in the management of patients with severe GI chronic GVHD.

Original languageEnglish (US)
Pages (from-to)49-51
Number of pages3
JournalJournal of Oncology Pharmacy Practice
Volume13
Issue number1
DOIs
StatePublished - Jun 15 2007
Externally publishedYes

Fingerprint

Graft vs Host Disease
Disease Management
Aminocaproic Acid
Hemorrhage
Fibrinolytic Agents
Blood Transfusion
Immunosuppression
Stomach
Stem Cells
Transplants
Therapeutics

Keywords

  • Aminocaproic acid
  • Anti-fibrinolytics
  • Gastrointestinal bleeding
  • Graft-versus-host disease

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Gastrointestinal chronic graft-versus-host disease : Management options. / Awan, Farrukh; Hamadani, Mehdi.

In: Journal of Oncology Pharmacy Practice, Vol. 13, No. 1, 15.06.2007, p. 49-51.

Research output: Contribution to journalArticle

@article{4f0845d88bc944a4bd3deebf2a22e0ba,
title = "Gastrointestinal chronic graft-versus-host disease: Management options",
abstract = "Chronic graft-versus-host disease (GVHD) is a common and debilitating condition afflicting a number of allogeneic stem cell recipients more than 100 days after their transplant. Limited options are available for the acute management of patients with severe gastrointestinal (GI) symptoms including gastric bleeding. Along with increased immunosuppression and aggressive supportive care, we report here the use of aminocaproic acid in the management of patients with GI bleeding resulting from severe GVHD. The use of aminocaproic acid enabled us to reduce the frequency and number of blood product transfusions required to manage our patient. Anti-fibrinolytic agents may therefore serve as useful adjunctive but underutilized therapy in the management of patients with severe GI chronic GVHD.",
keywords = "Aminocaproic acid, Anti-fibrinolytics, Gastrointestinal bleeding, Graft-versus-host disease",
author = "Farrukh Awan and Mehdi Hamadani",
year = "2007",
month = "6",
day = "15",
doi = "10.1177/1078155207077264",
language = "English (US)",
volume = "13",
pages = "49--51",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Gastrointestinal chronic graft-versus-host disease

T2 - Management options

AU - Awan, Farrukh

AU - Hamadani, Mehdi

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Chronic graft-versus-host disease (GVHD) is a common and debilitating condition afflicting a number of allogeneic stem cell recipients more than 100 days after their transplant. Limited options are available for the acute management of patients with severe gastrointestinal (GI) symptoms including gastric bleeding. Along with increased immunosuppression and aggressive supportive care, we report here the use of aminocaproic acid in the management of patients with GI bleeding resulting from severe GVHD. The use of aminocaproic acid enabled us to reduce the frequency and number of blood product transfusions required to manage our patient. Anti-fibrinolytic agents may therefore serve as useful adjunctive but underutilized therapy in the management of patients with severe GI chronic GVHD.

AB - Chronic graft-versus-host disease (GVHD) is a common and debilitating condition afflicting a number of allogeneic stem cell recipients more than 100 days after their transplant. Limited options are available for the acute management of patients with severe gastrointestinal (GI) symptoms including gastric bleeding. Along with increased immunosuppression and aggressive supportive care, we report here the use of aminocaproic acid in the management of patients with GI bleeding resulting from severe GVHD. The use of aminocaproic acid enabled us to reduce the frequency and number of blood product transfusions required to manage our patient. Anti-fibrinolytic agents may therefore serve as useful adjunctive but underutilized therapy in the management of patients with severe GI chronic GVHD.

KW - Aminocaproic acid

KW - Anti-fibrinolytics

KW - Gastrointestinal bleeding

KW - Graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=34250202254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250202254&partnerID=8YFLogxK

U2 - 10.1177/1078155207077264

DO - 10.1177/1078155207077264

M3 - Article

C2 - 17621568

AN - SCOPUS:34250202254

VL - 13

SP - 49

EP - 51

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 1

ER -